Skip to main content

Table 1 Clinical and biochemical profile

From: Obesity and high waist circumference are associated with low circulating pentraxin-3 in acute coronary syndrome

 

ACS

Control

Gender (M/F)

60/12

44/8

Age (years)

63 ± 10 (42–85)

62 ± 5 (54–73)

BMI (kg/m2)

27.5 ± 3.8 (20.6-40.8)

27.9 ± 3.6 (21.6-40.5)

WC (cm)

101 ± 10 (70–137)

100 ± 9 (80–118)

Prevalence (%)

  

Hypertension

68

62

Dyslipidemia

70

62

Type 2 Diabetes

16

12

Medications (%)

  

ACE-Inhib or ARB

48

42

Ca-Channel Blocker

18

20

Beta-Blockers

44

38

Diuretics

16

20

Statins

34

30

ASA

38

24

SBP (mmHg)

131 ± 18 (95–175)

136 ± 16 (115–165)

DBP (mmHg)

72 ± 10 (55–100)

76 ± 6 (70–95)

Creat (mg/dl)

1.01 ± 0.28 (0.55-1.5)

0.92 ± 0.20 (0.60-1.4)

Tg (mg/dl)

126 ± 65 (44–585)

146 ± 35 (110–289)

T-Chol (mg/dl)

191 ± 42 (81–316)

215 ± 41 (127–261)

HDL-Chol (mg/dl)

45 ± 8 (24–85)

48 ± 8 (32–65)

Glucose (mg/dl)

121 ± 26 (60–221)

114 ± 10 (86–131)

Insulin ( μU/ml)

4.6 ± 2.4 (1.5-12)

5.4 ± 3.3 (1.2-15.4)

HOMA-IR

1.45 ± 0.95 (0.3-4.8)

1.50 ± 0.96 (0.5-3.8)

CK (mU/ml)

124 (8.4-888)

-

Troponin (ng/ml)

14.6 (0.5-326)

-

CRP (mg/dl)

2 (0.2-15)

0.2 (0.02-3.1)*

PTX3 (ng/ml)

5.7 (1.8-29.3)

2.7 (1.2-5.6)*

  1. Gender, age, BMI, waist circumference (WC), disease prevalence, chronic medications (treatment before event for ACS); ACE-Inhib: Angiotensin Converting Enzyme-Inhibitors; ARB: Angiotensin Receptor Blockers; ASA: Acetylsalicylic Acid; systolic (SBP) and diastolic (DBP) blood pressure, plasma creatinine (creat), triglycerides (Tg), HDL cholesterol (HDL-Chol), glucose, insulin, Homeostasis Model Assessment (HOMA), plasma C-reactive protein (CRP) and pentraxin-3 (PTX3) in ACS and Control groups. Results are reported as Mean ± SD (Range) except for non-normally distributed HOMA-IR, CRP, PTX3, that are presented as Median (Range). *:P < 0.05 between ACS and Control groups by Wilcoxon test for non-normally distributed data (HOMA-IR, CRP, PTX3).